Table 1.
Study population | Third-dose recipients a | Fourth-dose recipients |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
Monovalent vaccine |
BA.1 bivalent vaccine |
BA.4–5 bivalent vaccine |
||||||
n | % | n | % | n | % | n | % | n | % | |
Sex | ||||||||||
Female | 227 290 | 55.70 | 214 120 | 55.60 | 142 665 | 55.04 | 18 621 | 53.38 | 13 781 | 54.00 |
Male | 180 783 | 44.30 | 170 744 | 44.40 | 116 514 | 44.96 | 16 260 | 46.62 | 11 741 | 46.00 |
Age (years) | ||||||||||
75–79 | 194 594 | 47.70 | 191 434 | 49.70 | 122 884 | 47.41 | 19 733 | 56.57 | 13 589 | 53.24 |
80–84 | 111 271 | 27.30 | 100 959 | 26.20 | 72 288 | 27.89 | 8596 | 24.64 | 6439 | 25.23 |
85–89 | 63 264 | 15.50 | 57 243 | 14.90 | 39 867 | 15.38 | 4355 | 12.49 | 3524 | 13.81 |
90+ | 38 944 | 9.50 | 35 228 | 9.20 | 24 140 | 9.31 | 2197 | 6.30 | 1970 | 7.72 |
Region | ||||||||||
Innlandet | 36 022 | 8.80 | 33 868 | 8.80 | 22 451 | 8.66 | 3808 | 10.92 | 2072 | 8.12 |
Trøndelag | 36 702 | 9.00 | 34 878 | 9 | 23 618 | 9.00 | 3038 | 9.00 | 1807 | 7.00 |
Nord-Norge | 39 775 | 9.70 | 38 615 | 10.00 | 20 636 | 7.96 | 3683 | 10.56 | 3264 | 12.79 |
Oslo & Viken | 133 582 | 32.70 | 123 735 | 32.20 | 87 962 | 33.94 | 10 611 | 30.42 | 9809 | 38.43 |
Agder & Sørøstlandet | 60 375 | 14.80 | 56 980 | 14.80 | 38 368 | 14.80 | 5074 | 14.55 | 4052 | 15.88 |
Vestlandet | 101 617 | 24.90 | 96 788 | 25.10 | 66 144 | 25.52 | 8667 | 24.85 | 4518 | 17.70 |
Risk group | ||||||||||
None | 189 581 | 46.50 | 179 726 | 46.70 | 120 725 | 46.58 | 16 549 | 47.44 | 11 973 | 46.91 |
Medium | 187 608 | 46.10 | 176 342 | 45.80 | 118 653 | 45.78 | 15 865 | 45.48 | 11 706 | 45.87 |
High | 30 884 | 7.60 | 28 796 | 7.50 | 19 801 | 7.64 | 2467 | 7.07 | 1843 | 7.22 |
LTCF resident | ||||||||||
No | 388 227 | 95.10 | 367 392 | 95.50 | 244 997 | 94.53 | 34 472 | 98.83 | 25 086 | 98.29 |
Yes | 19 846 | 4.90 | 17 472 | 4.50 | 14 182 | 5.47 | 409 | 1.17 | 436 | 1.71 |
LTCF, long-term care facility. n, number.
Individuals who received their third dose >24 weeks ago.